Antiplatelet, Antithrombotic Activity of Methanolic Leaf Extract of Terminalia Pallida Brandis

Year 2026, Volume: 30 Issue: 1, 85 - 93, 11.01.2026

Sarvan Kumar Guguloth , Ramya Krishna Ravuri Sadhana Noothi Madhavi Meesa Sravan Potturi

https://doi.org/10.12991/jrespharm.1666014

Abstract

Atherothrombotic diseases such as myocardial and cerebral infarctions are serious consequences of the thrombus formed in the blood vessels which are the most common causes of death worldwide. The present study aimed to evaluate the antiplatelet and antithrombotic activities of methanolic leaf extract of Terminalia pallida Brandis (METP). Antiplatelet property was carried by assessing bleeding time (BT) and collagen, adenosine diphosphate (ADP), and arachidonic acid (AA) induced platelet aggregation; whereas antithrombotic effects were assessed by measuring the coagulation parameters such as fibrinogen (Fb), thrombin time (TT), prothrombin time (PT), and activated partial thromboplastin time (aPTT). In this study, METP treatment significantly prolonged BT and inhibited ADP, collagen and AA induced platelet aggregation. Whereas, METP treatment also prolonged TT, PT and aPTT and reduced fibrinogen levels. Considering the in vivo, results the present investigation could be concluded that T. pallida Brandis (METP) leaf extract possess significant antiplatelet, antithrombotic properties.

Keywords

T. pallida Brandis , platelet aggregation , antithrombotic activity , antiplatelet activity.

Ethical Statement

regarding ethical approval, we got permission from vijaya college of pharmacy

References

• [1] Guguloth SK, Malothu N, Ganta NM, Ramakrishna K, Guntupalli C. Antiplatelet and antithrombotic properties of methanolic leaf extract of Plumbago zeylanica L. GC-MS and HR-LCMS metabolite profiling. S Afr J Bot. 2023; 159:627-634. https://doi.org/10.1016/j.sajb.2023.06.027.
• [2] Kim DW, Sapkota K, Choi JH, Kim YS, Kim S, Kim SJ. Direct acting anti-thrombotic serine protease from brown seaweed Costaria costata. Process Biochem. 2013 ; 48(2): 340-350. https://doi.org/10.1016/j.procbio.2012.12.012.
• [3] Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016;133(16):1605-1620. https://doi.org/10.1161/circulationaha.114.008729
• [4] Aje TO, Miller M. Cardiovascular disease: A global problem extending into the developing world. World J Cardiol. 2009;1(1):3-10. https://doi.org/10.4330/wjc.v1.i1.3
• [5] Nilsson IM. Coagulation and fibrinolysis. Scand J Gastroenterol Suppl. 1987;137:11-18. https://doi.org/10.3109/00365528709089754.
• [6] Heimburger N, Trobisch H. Blood coagulation and fibrinolysis. Angew Chem Int Ed Engl. 1971;10(2):85-97. https://doi.org/10.1002/anie.197100851
• [7] Stump DC, Mann KG. Mechanisms of thrombus formation and lysis. Ann Emerg Med. 1988;17(11):1138-1147. https://doi.org/10.1016/s0196-0644(88)80059-3.
• [8] Chen C, Yang FQ, Zhang Q, Wang FQ, Hu YJ, Xia ZN. Natural Products for Antithrombosis. Evid Based Complement Alternat Med. 2015;2015:876426. https://doi.org/10.1155/2015/876426.
• [9] Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Gonçalves N, Pinto FJ, Ferreira JJ, Costa J. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;1;101(15):1204-1211. https://doi.org/10.1136/heartjnl-2015-307489.
• [10] Yang SD, Liu H, Sun YP, Yang DL, Shen Y, Feng SQ, Zhao FD, Ding WY. Prevalence and risk factors of deep vein thrombosis in patients after spine surgery: a retrospective case-cohort study. Sci Rep. 2015; 2;5(1):11834. https://doi.org/10.1038/srep11834.
• [11] Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: a clinical review. J Blood Med. 2011;2:59-69. https://doi.org/10.2147/jbm.s19009.
• [12] Al-Hameed F, Al-Dorzi HM, Shamy A, Qadi A, Bakhsh E, Aboelnazar E, Abdelaal M, Al Khuwaitir T, Al-Moamary MS, Al-Hajjaj MS, Brozek J, Schünemann H, Mustafa R, Falavigna M. The Saudi clinical practice guideline for the diagnosis of the first deep venous thrombosis of the lower extremity. Ann Thorac Med. 2015;10(1):3-15. https://doi.org/10.4103/1817-1737.146849.
• [13] Musil D, Kaletová M, Herman J. Venous thromboembolism - prevalence and risk factors in chronic venous disease patients. Phlebology. 2017;32(2):135-140. https://doi.org/10.1177/0268355516633392.
• [14] Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008;38(1):15-23. https://doi.org/10.1016/j.transci.2007.12.005.
• [15] Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost. 2004;2(4):541-546. https://doi.org/10.1111/j.1538-7933.2004.00645.x.
• [16] Guguloth SK, Malothu N, Parasanth DSNBK. GC-MS analysis and thrombolytic property of methanolic leaf extracts of Terminalia pallida brandis against carrageenan instigated tail thrombosis model in mice. Pharmacogn Res. 2022;14(1):53-60. https://doi.org/10.5530/pres.14.1.9.
• [17] Fujita M, Hong K, Ito Y, Fujii R, Kariya K, Nishimuro S. Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biol Pharm Bull. 1995;18(10):1387-1391. https://doi.org/10.1248/bpb.18.1387.
• [18] Guguloth SK, Malothu N, Kulandaivelu U, Rao KG, Areti AR, Noothi S. Phytochemical investigation and In-vitro Thrombolytic activity of Terminalia pallida Brandis leaves. Res J Pharm Technol. 2021;14(2):879-882. https://doi.org/10.5958/0974-360X.2021.00156.6.
• [19] Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80(4A):11B-20B. https://doi.org/10.1016/s0002-9149(97)00572-9.
• [20] Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431-441. https://doi.org/10.1016/j.lfs.2005.09.012.
• [21] Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002; 24;277(21):18322-18333. https://doi.org/10.1074/jbc.M201173200